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Do integrins use a 'MIDAS touch' to grasp an Asp?
Integrins use divalent cations, held within a novel 'MIDAS' motif,
for ligand binding. It is proposed that a missing coordination site
for the cation is provided by a critical acidic residue in the ligand.
Integrins are cell-surface glycoproteins - each composed
of an and subunit - that mediate cell interactions
with a variety of ligands. Such ligands include extracellular
matrix proteins, counter-receptors on other cells, plasma
proteins and microbial pathogens. As integrins function in
such pathological processes as inflammation, thrombosis
and tumor metastasis, agents that block integrin-ligand
interactions could be of great therapeutic value, and many
laboratories have sought to define the structures involved.
Despite their obvious interest, however, these large and
complex proteins have been unwilling subjects for X-ray
crystallographic analysis. Now Lee et al. [1] have deter-
mined the crystal structure of a ligand-binding domain
within the oaM subunit of the leukocyte integrin CR3. In
another significant advance, Jones et al. [2] have deter-
mined the partial structure of an integrin ligand, the
vascular cell-adhesion molecule VCAM-1.
A ligand-binding domain within an integrin oz subunit
The aM132 integrin (also called CR3, CDllb/CD18 or
Mac-1) is present on phagocytic cells and is involved
both in leukocyte adhesion to endothelium and in the
internalization of opsonized microorganisms. CR3 lig-
ands include the complement component iC3b, the
intercellular adhesion molecule ICAM-1, and the coag-
ulation factors fibrinogen and factor X. Within CR3,
the olM subunit contains a 200 amino-acia inserted
domain, referred to by many investigators as the I do-
main. Similar I-domain regions are found in 6 of the 15
known integrin ao subunits. As they show homology to
the collagen-binding A domains of von Willebrand fac-
tor, it had long been suspected that the integrin I (or A)
domains were involved in ligand binding. This was
first demonstrated when function-blocking monoclonal
antibody epitopes were mapped to the aM I-domain
region [3], and site-specific mutations within the I
domain abolished integrin attachment to ligand [4].
More recently, isolated integrin I domains were synthe-
sized as bacterial fusion proteins, and were shown by five
different groups to bind directly to a variety of ligands
(listed in [5]).
Lee et al. [1] have determined the structure of such a
recombinant protein. The integrin otaM I domain consists
of a central sheet surrounded by seven helices
(Fig. 1). The amino and carboxyl termini of the recom-
binant peptide emerge from the base of the globular
domain, where they would presumably be joined to the
body of the o subunit. Situated at the opposite pole is a
single magnesium ion, coordinated by five oxygenated
amino acids - the sequence DXSXS (in the single-letter
amino-acid code, with X representing any amino acid),
plus non-contiguous aspartate and threonine residues
downstream. A similar pattern of oxygenated residues,
which the authors characterize as the 'metal ion-depen-
dent adhesion site' (MIDAS) motif, is present within all
integrin I domains, and there is strong evidence for its role
in integrin-ligand interactions. Divalent cations are critical
for integrin interactions with almost all ligands [6], and
mutagenesis of amino acids that comprise the MIDAS
motif is known to prevent ligand binding [4,7]. Interest-
ingly, within the crystal structure, an acidic residue derived
from a neighboring I domain provides a sixth magnesium
coordination site (Fig. 2). The authors propose that,
under physiological conditions, the sixth coordination
site might be provided by an acidic ligand residue.
The paper by Lee et al. [1] provides a first view of
integrin-ligand interactions, but the picture is far from
complete and several issues remain to be explored. Many
integrins, including the receptor for VCAM-1 (the
structure of which is described below), do not contain I
domains within their a subunits. For those integrins
that do have I domains, specificity for particular ligands
Fig. 1. Schematic diagram of the aM I domain. The magnesium
ion is shown as a blue ball. Figure provided by R. Liddington;
adapted from [1 ].
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Fig. 2. The MIDAS site. The magnesium ion is coordinated by
oxygen atoms, shown in red. Three coordination sites are pro-
vided by serines 142 and 144, and threonine 209, and two by
water molecules (wi and w2) bound by aspartates 140 and 242.
The magnesium ion also interacts with a glutamate residue(E 314) derived from a neighboring I domain within the crystal
structure. Ligand binding may involve an interaction between the
integrin divalent cation and an acidic amino acid in the ligand.
Figure provided by R. Liddington; adapted from [1].
Jones et al. [2] also shows a critical integrin-binding motif
(QIDSPL) present within a flexible loop between two 3
strands (see Fig. 3). This structure for VCAM-1 is the
first to be reported for a member of the integrin-binding
subgroup of the immunoglobulin superfamily. Thus, this
finding helps bring into focus some distinctive features of
this immunoglobulin subgroup, which includes VCAM-
1, MadCAM, and ICAMs -1, -2 and -3. Each has a con-
served extra disulfide bond, which is now shown in the
VCAM-1 domain 1 to link the BC and FG loops at the
top of the immunoglobulin domain barrel. Most impor-
tantly, each also has an integrin-binding motif, related
to QIDSPL, shown in the VCAM-1 domain 1 structure
to be prominently displayed at the end of the CD loop
(Fig. 3). Within the QIDSPL sequence, mutagenesis has
consistently shown that Asp 40 may be most critical
residue for ligand binding [11,12].
must involve non-conserved amino acids as well as the
conserved MIDAS residues. Furthermore, the 'MIDAS
touch' may be less relevant for unusual integrin ligands,
such as the pathogen echovirus 1, as their binding is
cation-independent. The eventual development of selec-
tive therapeutic agents will depend on understanding
how specific integrins fit their particular ligands.
Several lines of evidence indicate that regions within
the as well as the ot subunits of integrins are involved
in integrin-ligand interactions (reviewed in [6]). The
DXSXS motif is present in all eight of the known inte-
grin subunits, at a putative binding site implicated by
ligand crosslinking studies. Replacement of these oxy-
genated residues within the subunit abolishes ligand
binding, even for I domain-containing integrins such as
CR3 [8]. Thus, it is a quite fascinating possibility that
integrin subunits might also contain a MIDAS-like
motif within a ligand-binding region that is structurally
related to the ot subunit I domain [1].
An integrin recognition site within the ligand VCAM-1
Many integrin ligands contain an Arg-Gly-Asp (RGD)
motif that is essential for cell adhesion [9]. Within the
tenth type-II repeat of fibronectin, the RGD is present
within a conformationally mobile loop [10], thus allow-
ing ready accessibility for integrin recognition. Although
there is no obvious sequence similarity between fibro-
nectin type-III repeats and immunoglobulin domains,
they are topologically quite similar [10]: each is barrel
shaped, with two facing sheets, and each sheet is
composed of three or four antiparallel strands.
Analogous to the location of the RGD sequence within
the fibronectin type-III repeat, the recent crystal struc-
ture of VCAM-1 immunoglobulin domains 1 and 2 by
Fig. 3. Crystal structure of VCAM-1 immunoglobulin domains 1
and 2. The region on the CFG face interacting with integrin is
marked with red dots. The critical Asp 40 residue in the CF loop
is indicated by an asterisk. Figure provided by E.Y. Jones and D.I.
Stuart; adapted from [2].
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Although the QIDSPL sequence is critical, it obviously
does not solely determine integrin specificity, as the
QIDS sequence in VCAM-1 can be replaced by GIET
(derived from ICAM-1) without preventing binding to
the receptor, VLA-4 [11]. Several other residues on the
face of the CFG 13 sheet in the VCAM domain 1 also
contribute to ligand binding (Fig. 3). This finding points
to an emerging trend among immunoglobulin-like pro-
teins involved in adhesive interactions, as the CFG faces
of the adhesive proteins CD2 [13] and E-cadherin [14]
also contain critical sites for ligand binding.
Within the subgroup of integrin-binding immuno-
globulin domain proteins, domain-1 BC loops and
domain-2 C'E loops show important differences among
MAdCAM, VCAM and the three ICAMs, and thus
could be critical elements for determining ligand speci-
ficity [2]. It is intriguing that the shortest domain-i BC
loops and domain-2 C'E loops are found in the ICAMs,
which are ligands for integrins that contain I domains. In
contrast, the longer BC and C'E loops of VCAM and
MadCAM correlate with binding to 4131 and oL4 37 inte-
grins that lack I domains. The VCAM-1 domain-2
structure also contains a typical immunoglobulin-type
topology, but it has not yet been found to contain
residues directly implicated in ligand binding. Nonethe-
less, the proximity of the domain-2 C'E and FG loops to
the integrin-binding region in domain 1 suggests possible
targets for future mutagenesis.
So far, integrin ligands all contain acidic residues (usually
aspartate, sometimes glutamate) as a key feature of their
integrin-binding motifs. As is true for the RGD and
QIDSPL motifs described above, we predict that other
recognition motifs (such as the LDV site within fibro-
nectin, recognised by VLA-4) will also be found within
flexible loops, where they may be available for integrin
recognition. In this regard, it is quite intriguing to find
that each of five different cadherins all contain aspartates
in the middle of immunoglobulin-like CD loops [14],
considering the recent evidence that a cadherin can be
recognized by an integrin [15].
The notion that all integrins may contain at least one,
and sometimes two MIDAS motifs, neatly fits the con-
cept of acidic ligand residues providing missing divalent
cation coordinations. This paradigm represents an impor-
tant start towards understanding integrin-ligand inter-
actions. An obvious challenge for the future will be to
coordinate the contributions of both et and 13 integrin
chains to ligand binding. An even bigger challenge for
structural biologists will be to elucidate the perhaps sub-
tle conformational changes that accompany integrin acti-
vation, and to understand the substantial conformational
changes that apparently occur as a result of ligand binding
and contribute to signaling from the outside of the cell to
the inside.
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